Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
about
P1343
Addition of pamidronate to chemotherapy for the treatment of osteosarcomaPhenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcomaBone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaAnti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidencesZoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.Direct antitumour activity of zoledronic acid: preclinical and clinical data.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcomaInduction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcomaZoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cellsAnticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastasesGenetically engineered mouse models and human osteosarcoma.Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKLLiposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.The Current and Future Therapies for Human Osteosarcoma.Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection statusRecent advances in the management of osteosarcoma and forthcoming therapeutic strategies.L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupRANK and RANK ligand expression in primary human osteosarcoma.Changing the clinical picture of challenging tumors: tales becoming reality?Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis.Emerging drugs for high-grade osteosarcoma.Pharmacokinetic evaluation of zoledronic acid.Potential of human γδ T cells for immunotherapy of osteosarcoma.Targeted therapies for bone sarcomas.Bone microenvironment signals in osteosarcoma development.Novel insights and therapeutic interventions for pediatric osteosarcoma.Drugs in early clinical development for the treatment of osteosarcoma.Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review.Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models.Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.Bone sarcomas: from biology to targeted therapies.Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.Biology of Bone Sarcomas and New Therapeutic Developments.CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phaNovel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation.Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations.
P2860
Q24594269-72300558-428E-45E5-B5AE-06BA557E65C6Q24814867-D20B6B9C-AC17-4DAD-A3C9-37ECA1D2AE60Q26771376-42D4F22A-0AC0-43DB-9A9C-0434C9B2E4E3Q26863493-6895177A-328A-4769-A78D-E3680ACF0F1EQ33273281-243483F6-0D94-40D8-9B8E-F1DAC3C01B4FQ33850938-B93B1175-EB43-4C14-B60D-1355DADD020EQ34145863-856DAFA6-7E11-48C8-B34B-4D25EA5E1138Q34365891-ED9639EC-B88B-4755-8B16-462452A0F9DAQ34786566-A3E6B40F-6013-4644-9F54-0862EFA8B37DQ35115510-1ED1388B-34FD-48D8-8153-D64C1CFB21BCQ35458425-63A0E8E3-0E0B-486E-9EA6-A4C1D3A4AC31Q35987375-82A474EA-579D-4492-8B18-E18C2A15111AQ36468644-55D6845B-B3C2-423B-9758-C01929878FBBQ36491545-901F86A4-2FE6-4E2C-BB19-BE789EA04D9FQ36512499-1835588F-A20E-4178-8590-F3B649D7953DQ36514299-01985AA2-005D-41B3-8E6D-BBED6D584479Q36661456-4E77AC45-C495-4F3C-A60D-D6311CD31B20Q36731426-5D89C817-B405-4A2B-B84E-E2FE7F3C4945Q36853886-41F31926-31A6-4D5B-9BC9-5CFE6210CDCBQ36946864-C8A745F0-BC3D-4906-8D5D-6AB60BFEFBABQ37179783-307D3284-B902-4DFD-B412-E2ED869721F0Q37575602-1BC401B9-BAFE-4A22-8ADB-375E0966AB13Q37707525-BD208391-6364-4758-AA4A-8FB2ABE522FBQ37778400-E6ED57D4-3121-414F-A4DF-976490E22833Q37874629-7BB8CB0E-7CF7-4119-B5DC-61112C1E1D06Q38052064-8C32A54C-8A45-4220-9820-02E2B96E228EQ38178277-87F690FC-E853-401B-A7E0-45F5700ECD45Q38454980-01FFCF23-2A13-42EA-8188-B8199C7FF35FQ38819276-76347665-5296-4515-9FF7-E31FA09A7DFFQ38955517-6EF5ACD8-EB8B-41B1-8009-3A727A398D4EQ38990116-F142E477-0255-4919-8F5C-59126EC84B16Q39640530-DA93C060-1C73-47B0-8076-3EA5DD4C51CCQ39751683-FFB3E1BA-66DF-4160-ABE6-0A2DBDFA352BQ41497465-522C842F-A6CC-4F31-A0B1-920FF7F82A0EQ41923624-93ED4057-D465-4686-AAD5-2F3D3CEE5E5EQ42277867-BDA9BF18-0363-4D43-AA4C-A850CEB78165Q48120956-17F547B6-0F1A-46B6-B506-CC589C91353DQ50481939-33E2A93B-0E36-4494-87C3-0095E3F872BAQ51760981-97979A12-7F05-49D9-A735-A636E9947966Q55033636-8D14E21D-2BEA-4E5E-9C12-12A0FF8B0F23
P2860
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Enhanced tumor regression and ...... fosfamide in rat osteosarcoma.
@ast
Enhanced tumor regression and ...... fosfamide in rat osteosarcoma.
@en
type
label
Enhanced tumor regression and ...... fosfamide in rat osteosarcoma.
@ast
Enhanced tumor regression and ...... fosfamide in rat osteosarcoma.
@en
prefLabel
Enhanced tumor regression and ...... fosfamide in rat osteosarcoma.
@ast
Enhanced tumor regression and ...... fosfamide in rat osteosarcoma.
@en
P2093
P1433
P1476
Enhanced tumor regression and ...... fosfamide in rat osteosarcoma.
@en
P2093
Blanchard F
Charrier C
Couillaud S
Heymann MF
P356
10.1016/J.BONE.2005.02.020
P4510
P577
2005-07-01T00:00:00Z